Table 3 Percentage of low risk of bias studies per treatment arm in the meta-analysis on exacerbation rate [13, 15, 19, 33,34,35,36,37,38,39,40,41,42]
From: Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis
Treatment | Percentage |
|---|---|
Benralizumab | 60% (3/5) |
Lebrikizumab | 50% (1/2) |
Dupilumab | 0% (0/1) |
Mepolizumab | 50% (1/2) |
Tralokinumab | 100% (1/1) |
Reslizumab | 100% (1/1) |
Tezepelumab | 100% (1/1) |